OPKO Health Inc (OPK)
1.245
+0.02
(+1.22%)
USD |
NASDAQ |
Apr 15, 16:00
1.245
0.00 (0.00%)
After-Hours: 20:00
OPKO Health Research and Development Expense (Quarterly): 19.39M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 19.39M |
| September 30, 2023 | 19.44M |
| June 30, 2023 | 18.16M |
| March 31, 2023 | 32.60M |
| December 31, 2022 | 19.53M |
| September 30, 2022 | 18.79M |
| June 30, 2022 | 17.25M |
| March 31, 2022 | 18.31M |
| December 31, 2021 | 21.01M |
| September 30, 2021 | 18.31M |
| June 30, 2021 | 18.22M |
| March 31, 2021 | 19.32M |
| December 31, 2020 | 17.45M |
| September 30, 2020 | 18.49M |
| June 30, 2020 | 17.61M |
| March 31, 2020 | 21.76M |
| December 31, 2019 | 23.04M |
| September 30, 2019 | 30.02M |
| June 30, 2019 | 28.29M |
| March 31, 2019 | 36.53M |
| December 31, 2018 | 33.33M |
| September 30, 2018 | 30.16M |
| June 30, 2018 | 29.21M |
| March 31, 2018 | 32.89M |
| December 31, 2017 | 34.24M |
| Date | Value |
|---|---|
| September 30, 2017 | 32.51M |
| June 30, 2017 | 33.13M |
| March 31, 2017 | 26.56M |
| December 31, 2016 | 30.28M |
| September 30, 2016 | 24.42M |
| June 30, 2016 | 31.35M |
| March 31, 2016 | 27.82M |
| December 31, 2015 | 25.48M |
| September 30, 2015 | 18.94M |
| June 30, 2015 | 29.57M |
| March 31, 2015 | 25.50M |
| December 31, 2014 | 25.83M |
| September 30, 2014 | 20.52M |
| June 30, 2014 | 16.23M |
| March 31, 2014 | 20.99M |
| December 31, 2013 | 23.35M |
| September 30, 2013 | 11.08M |
| June 30, 2013 | 9.557M |
| March 31, 2013 | 9.91M |
| December 31, 2012 | 6.578M |
| September 30, 2012 | 3.621M |
| June 30, 2012 | 4.49M |
| March 31, 2012 | 4.831M |
| December 31, 2011 | 4.255M |
| September 30, 2011 | 3.301M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
17.25M
Minimum
Jun 2022
32.60M
Maximum
Mar 2023
20.89M
Average
19.32M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Innerscope Hearing Technologies Inc | -- |
| Retractable Technologies Inc | 0.1617M |
| Stryker Corp | 350.00M |
| Perspective Therapeutics Inc | 6.08M |
| Xtant Medical Holdings Inc | 0.492M |